查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1933363

全球氨基糖苷类抗生素市场：市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的考量因素及未来预测（2026-2034）

Aminoglycosides Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 167 Pages | 商品交期: 请询问到货日

价格

氨基糖苷类抗生素市场成长驱动因子

预计2025年全球氨基糖苷类抗生素市场规模将达19.2亿美元，2026年将达19.6亿美元。预计2034年将成长至25.2亿美元，预测期内复合年增长率（CAGR）为3.17%。北美地区凭藉其完善的医疗保健基础设施、强大的购买力和许多大型企业的强大影响力，在2025年占市场主导地位，市场占有率达41.31%。氨基糖苷类抗生素是一类广泛用于治疗复杂性泌尿道感染（cUTI）、败血症、医院获得性肺炎、囊性纤维化等呼吸系统疾病的杀菌性抗生素。 新霉素、妥布霉素、庆大霉素、阿米卡星、巴龙霉素和链霉素等药物因其与β-内酰胺类抗生素对多重抗药性细菌具有协同作用，尤其是在重症监护病房中，在临床实践中继续发挥着重要作用。吸入製剂和半合成衍生物等技术进步提高了药物传递效率和安全性。 Hikma Pharmaceuticals、辉瑞和Cipla等领导者凭藉丰富的产品组合和地理扩张，保持着市场主导地位。 市场动态 驱动因素：泌尿道感染（UTI）发生率的上升推动了氨基糖苷类药物处方量的增加。导致这一增长的因素包括人口老化、糖尿病盛行率上升以及发展中地区医院感染的流行。例如，2024年2月，印度药品监管局（CDSCO）批准了西普拉公司（Cipla）的新型静脉注射氨基糖苷类抗生素普拉佐米星（plazomicin），用于治疗包括肾盂肾炎在内的复杂性泌尿道感染。

限制因素：抗菌药物抗药性（AMR）的出现威胁着市场成长。大肠桿菌、肺炎克雷伯菌和绿脓桿菌的抗药性日益增强，使治疗效果复杂化。 2023年7月，美国疾病管制与预防中心（CDC）报告称，耐碳青霉烯类肠桿菌科细菌（CRE）和抗氨基糖苷类革兰氏阴性菌的数量增加。同样，欧洲疾病预防控制中心（ECDC）指出，在多个欧盟国家，肺炎克雷伯菌血流感染的抗药性率超过25%。

机会：肽链氨基糖苷类药物的开发可望用于对抗多重抗药性病原体。 2025年8月发表于 "微生物学前沿" （Frontiers in Microbiology）的一项研究强调了肽新霉素复合物与多粘菌素B联合用药对多重抗药性革兰氏阴性菌的协同作用，表明其具有广阔的应用前景。

挑战：耳毒性和肾毒性仍然是主要问题。即使在治疗剂量下，携带罕见粒线体突变的患者也容易出现不可逆的听力丧失。 2021年1月，英国政府报告​​称，氨基糖苷类药物的治疗窗较窄，凸显了其在急诊环境中的临床挑战，并限制了其广泛应用。

市场趋势

联合疗法的应用正日益普及。 氨基糖苷类药物目前常被纳入多重药物合併疗法，用于治疗由鸟分枝桿菌复合群 (MAC) 引起的非结核分枝桿菌 (NTM) 肺病等疾病。这种方法可以提高疗效，延缓抗药性的产生，并延长现有抗生素的治疗寿命。 2021 年 3 月，Insmed 公司在日本核准上市的 Arikace（阿米卡星脂质体吸入混悬液），这是一种用于治疗非结核分枝桿菌 (NTM) 肺病的联合疗法。

市场区隔分析

依世代划分：第三代氨基糖苷类药物因其对多重抗药性感染的有效性而占主导地位。诸如四环药业控股有限公司与上海盛亚医药股份有限公司于 2022 年 6 月达成的合作协议等战略联盟，为普拉唑米星等第三代药物的研发提供了支持。

依适应症划分：呼吸道感染占比最大。这主要是由于呼吸道感染的高发生率和治疗复杂性，尤其是在囊性纤维化患者。美国疾病管制与预防中心 (CDC) 在 2024 年 5 月报告称，美国约有 35,000 人患有囊性纤维化，这推动了对氨基糖苷类药物的需求。

依给药途径划分：外用製剂因其局部疗效、全身吸收少以及新产品不断上市而占主导地位。例如，Apili Therapeutics 于 2024 年 10 月开发了用于治疗皮肤利甚曼病的外用巴龙霉素製剂 ATI-1801。

依分销管道划分：零售药局因其便利性、病患信任度和不断扩大的网路而处于领先地位。 2024年9月，Pharmaprix在魁北克省扩建了其护理诊所，以改善氨基糖苷类药物的可及性。

区域展望

北美：在策略合作、研发投资和强大的医疗保健体系的支持下，预计到2025年，市场规模将达到7.9亿美元。

欧洲：在强大的医疗保健基础设施和抗菌药物管理计画的支持下，预计到2025年，市场规模将达到4.9亿美元，成长率为2.80%。

亚太地区：预计到2025年，市场规模将达到3.2亿美元，这反映了抗生素可近性的扩大和传染病患者病率的上升。

拉丁美洲、中东和非洲：受医疗保健支出成长的推动，预计拉丁美洲市场将成长2亿美元，中东和非洲市场也将成长，但增幅较小，预计成长速度将较为温和。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：关键考虑因素

  • 各国及地区主要疾病概览（2025 年）
  • 各国及地区监理现况（2025 年）
  • 主要公司产品线分析
  • 抗生素治疗指引概览
  • 世卫组织重点病原体抗生素抗药性概览
  • 主要产业趋势：併购、业务合作等等。

第五章 全球氨基糖苷类抗生素市场分析：洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依代划分
    • 第一代
    • 第二代
    • 第三代
    • 其他
  • 市场分析、洞察与预测：依应用划分
    • 泌尿道感染
    • 呼吸道感染
    • 皮肤感染
    • 眼部感染
    • 其他
  • 市场分析、洞察与预测：依给药途径划分
    • 口服
    • 肠外给药
    • 外用
    • 其他
  • 市场分析、洞察与预测：依通路划分
    • 医院药房
    • 零售药房
    • 线上药房
  • 市场分析、洞察与预测：依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章 北美氨基糖苷类抗生素市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第七章 欧洲氨基糖苷类抗生素市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 德国
    • 美国王国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚
    • 欧洲其他地区

第八章：亚太地区氨基糖苷类抗生素市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 中国
    • 日本
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章：拉丁美洲氨基糖苷类抗生素市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

章节10：中东和非洲氨基糖苷类抗生素市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 海湾合作委员会 (GCC) 国家
    • 南非
    • 中东和非洲其他地区

第 11 章 竞争分析

  • 全球市占率分析（2025）
  • 公司简介
  • Amneal Pharmaceuticals, Inc.
  • Hikma Pharmaceuticals PLC
  • Insmed Incorporated
  • Pfizer Inc.
  • Cipla
  • Nordic Group B.V.
  • Lupin
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Ltd.
Product Code: FBI113880

Growth Factors of aminoglycosides Market

The global aminoglycosides market was valued at USD 1.92 billion in 2025 and is projected to reach USD 1.96 billion in 2026, eventually growing to USD 2.52 billion by 2034, reflecting a CAGR of 3.17% during the forecast period. North America dominated the market in 2025 with a 41.31% share, owing to robust healthcare infrastructure, high purchasing capacity, and a strong presence of key players. Aminoglycosides are a class of bactericidal antibiotics widely employed in treating complicated urinary tract infections (cUTIs), sepsis, nosocomial pneumonia, and respiratory diseases like cystic fibrosis. Drugs such as neomycin, tobramycin, gentamicin, amikacin, paromomycin, and streptomycin remain vital in clinical practice, particularly in critical care settings due to their synergy with B-lactam antibiotics against multidrug-resistant organisms. Technological advances, including inhaled forms and semi-synthetic derivatives, have improved drug delivery and safety profiles. Leading companies like Hikma Pharmaceuticals PLC, Pfizer Inc., and Cipla maintain market dominance through extensive product portfolios and geographic expansion.

Market Dynamics

Drivers: Rising incidences of urinary tract infections (UTIs) have increased aminoglycoside prescriptions. Factors such as an aging population, higher prevalence of diabetes, and hospital-acquired infections in developing regions have contributed to this growth. For instance, in February 2024, Cipla Limited received approval from India's CDSCO for Plazomicin, a new IV aminoglycoside indicated for complicated UTIs, including pyelonephritis.

Restraints: The emergence of antimicrobial resistance (AMR) threatens market growth. Resistance in Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa has been rising, complicating treatment outcomes. In July 2023, the U.S. CDC reported an increase in carbapenem-resistant Enterobacteriaceae (CRE) and aminoglycoside-resistant gram-negative bacteria. Similarly, the ECDC noted resistance in K. pneumoniae bloodstream infections exceeding 25% in multiple EU countries.

Opportunities: Development of peptide-linked aminoglycoside conjugates offers potential to combat multidrug-resistant pathogens. In August 2025, a study published in Frontiers in Microbiology highlighted that peptide-neomycin conjugates combined with polymyxin B show synergistic activity against multidrug-resistant gram-negative bacteria, presenting a promising growth avenue.

Challenges: Ototoxicity and nephrotoxicity remain major concerns. Patients with rare mitochondrial mutations are particularly susceptible to irreversible hearing loss, even at therapeutic doses. In January 2021, the UK government reported the narrow therapeutic window of aminoglycosides, highlighting the clinical challenges in urgent care settings and limiting adoption.

Market Trends

The market is witnessing increased adoption of combination therapy. Aminoglycosides are now frequently integrated into multidrug regimens for conditions like NTM lung disease caused by Mycobacterium avium complex (MAC). This approach enhances efficacy, slows resistance development, and extends the therapeutic lifespan of existing antibiotics. In March 2021, Insmed Inc. received approval in Japan for ARIKAYCE (amikacin liposome inhalation suspension), a combination therapy for NTM lung disease.

Segmentation Analysis

By Generation: The third-generation aminoglycosides dominate due to effectiveness against multidrug-resistant infections. Strategic collaborations, such as the June 2022 agreement between Sihuan Pharmaceutical Holdings Group Ltd. and Shanghai SPH New Asia Pharmaceutical Co., Ltd., support the development of third-generation drugs like Plazomicin.

By Application: Respiratory tract infections hold the largest share due to their prevalence and treatment complexity, particularly in cystic fibrosis patients. The CDC reported in May 2024 that approximately 35,000 people in the U.S. are affected by cystic fibrosis, driving aminoglycoside demand.

By Route of Administration: The topical segment dominates due to localized efficacy, minimal systemic absorption, and novel product launches. For example, Appili Therapeutics Inc. developed ATI-1801, a topical paromomycin formulation for cutaneous leishmaniasis, in October 2024.

By Distribution Channel: Retail pharmacies lead due to accessibility, patient trust, and network expansion. In September 2024, Pharmaprix expanded its care clinics in Quebec, improving access to aminoglycosides.

Regional Outlook

North America: Dominates with USD 0.79 billion in 2025, driven by strategic collaborations, R&D investments, and a robust healthcare system.

Europe: Projected to reach USD 0.49 billion in 2025 with a 2.80% growth rate, supported by strong healthcare infrastructure and antimicrobial stewardship programs.

Asia Pacific: Estimated at USD 0.32 billion in 2025, reflecting increasing access to antibiotics and rising infection prevalence.

Latin America & Middle East & Africa: Moderate growth is expected, with USD 0.20 billion in Latin America and smaller contributions from the Middle East & Africa, fueled by increasing healthcare expenditure.

Competitive Landscape

The market exhibits a semi-concentrated structure. Key players like Amneal Pharmaceuticals, Hikma Pharmaceuticals, Cipla, Pfizer Inc., and Insmed Incorporated focus on product innovation, partnerships, and geographic expansion. Notable developments include Nordic Pharma's generic Maxitrol launch in April 2025 and Lupin's Tobramycin inhalation solution FDA approval in June 2018.

Conclusion

The global aminoglycosides market is set to grow from USD 1.92 billion in 2025 to USD 1.96 billion in 2026, reaching USD 2.52 billion by 2034 at a CAGR of 3.17%. Growth is driven by rising urinary tract and respiratory infections, combination therapy adoption, and ongoing R&D to overcome antimicrobial resistance. Challenges such as toxicity risks and resistance issues exist, but advancements in formulation, delivery technologies, and peptide-linked aminoglycosides present significant opportunities. Key players' strategic collaborations and product launches reinforce their market position, ensuring sustained growth over the forecast period.

Segmentation By Generation

  • First Generation
  • Second Generation
  • Third Generation
  • Others

By Application

  • Urinary Tract Infections
  • Respiratory Tract Infection
  • Skin Infections
  • Ophthalmic Infections
  • Others

By Route of Administration

  • Oral
  • Parenteral
  • Topical
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Geography

  • North America (By Generation, Application, Route of Administration, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Generation, Application, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Generation, Application, Route of Administration, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Generation, Application, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Generation, Application, Route of Administration, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Overview of Key Diseases, By Key Countries/ Region, 2025
  • 4.2. Regulatory Scenario by Key Countries/ Region, 2025
  • 4.3. Pipeline Analysis, By Key Players
  • 4.4. Overview of Antimicrobial Treatment Guidelines
  • 4.5. Overview of the Antibiotic resistant "Priority Pathogens" Published by WHO
  • 4.6. Key Industry Developments- Mergers, Acquisitions, Partnerships, etc.

5. Global Aminoglycosides Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Generation
    • 5.1.1. First Generation
    • 5.1.2. Second Generation
    • 5.1.3. Third Generation
    • 5.1.4. Others
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Urinary Tract Infections
    • 5.2.2. Respiratory Tract Infection
    • 5.2.3. Skin Infections
    • 5.2.4. Opthalmic Infections
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Oral
    • 5.3.2. Parenteral
    • 5.3.3. Topical
    • 5.3.4. Others
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacy
    • 5.4.2. Retail Pharmacy
    • 5.4.3. Online Pharmacy
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Aminoglycosides Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Generation
    • 6.1.1. First Generation
    • 6.1.2. Second Generation
    • 6.1.3. Third Generation
    • 6.1.4. Others
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Urinary Tract Infections
    • 6.2.2. Respiratory Tract Infection
    • 6.2.3. Skin Infections
    • 6.2.4. Opthalmic Infections
    • 6.2.5. Others
  • 6.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.3.1. Oral
    • 6.3.2. Parenteral
    • 6.3.3. Topical
    • 6.3.4. Others
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital Pharmacy
    • 6.4.2. Retail Pharmacy
    • 6.4.3. Online Pharmacy
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Aminoglycosides Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Generation
    • 7.1.1. First Generation
    • 7.1.2. Second Generation
    • 7.1.3. Third Generation
    • 7.1.4. Others
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Urinary Tract Infections
    • 7.2.2. Respiratory Tract Infection
    • 7.2.3. Skin Infections
    • 7.2.4. Opthalmic Infections
    • 7.2.5. Others
  • 7.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.3.1. Oral
    • 7.3.2. Parenteral
    • 7.3.3. Topical
    • 7.3.4. Others
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital Pharmacy
    • 7.4.2. Retail Pharmacy
    • 7.4.3. Online Pharmacy
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. Germany
    • 7.5.2. U.K.
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Aminoglycosides Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Generation
    • 8.1.1. First Generation
    • 8.1.2. Second Generation
    • 8.1.3. Third Generation
    • 8.1.4. Others
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Urinary Tract Infections
    • 8.2.2. Respiratory Tract Infection
    • 8.2.3. Skin Infections
    • 8.2.4. Opthalmic Infections
    • 8.2.5. Others
  • 8.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.3.1. Oral
    • 8.3.2. Parenteral
    • 8.3.3. Topical
    • 8.3.4. Others
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital Pharmacy
    • 8.4.2. Retail Pharmacy
    • 8.4.3. Online Pharmacy
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Aminoglycosides Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Generation
    • 9.1.1. First Generation
    • 9.1.2. Second Generation
    • 9.1.3. Third Generation
    • 9.1.4. Others
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Urinary Tract Infections
    • 9.2.2. Respiratory Tract Infection
    • 9.2.3. Skin Infections
    • 9.2.4. Opthalmic Infections
    • 9.2.5. Others
  • 9.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.3.1. Oral
    • 9.3.2. Parenteral
    • 9.3.3. Topical
    • 9.3.4. Others
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital Pharmacy
    • 9.4.2. Retail Pharmacy
    • 9.4.3. Online Pharmacy
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Aminoglycosides Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Generation
    • 10.1.1. First Generation
    • 10.1.2. Second Generation
    • 10.1.3. Third Generation
    • 10.1.4. Others
  • 10.2. Market Analysis, Insights and Forecast - By Application
    • 10.2.1. Urinary Tract Infections
    • 10.2.2. Respiratory Tract Infection
    • 10.2.3. Skin Infections
    • 10.2.4. Opthalmic Infections
    • 10.2.5. Others
  • 10.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.3.1. Oral
    • 10.3.2. Parenteral
    • 10.3.3. Topical
    • 10.3.4. Others
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital Pharmacy
    • 10.4.2. Retail Pharmacy
    • 10.4.3. Online Pharmacy
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability))
    • 11.2.1. Amneal Pharmaceuticals, Inc.
    • 11.2.2. Hikma Pharmaceuticals PLC
    • 11.2.3. Insmed Incorporated
    • 11.2.4. Pfizer Inc.
    • 11.2.5. Cipla
    • 11.2.6. Nordic Group B.V.
    • 11.2.7. Lupin
    • 11.2.8. Sun Pharmaceutical Industries Ltd.
    • 11.2.9. Dr. Reddy's Laboratories Ltd.

List of Tables

  • Table 1: Global Aminoglycosides Market Revenue (USD billion) Forecast, by Generation, 2021-2034
  • Table 2: Global Aminoglycosides Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 3: Global Aminoglycosides Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 4: Global Aminoglycosides Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 5: Global Aminoglycosides Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 6: North America Aminoglycosides Market Revenue (USD billion) Forecast, by Generation, 2021-2034
  • Table 7: North America Aminoglycosides Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 8: North America Aminoglycosides Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 9: North America Aminoglycosides Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 10: North America Aminoglycosides Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 11: Europe Aminoglycosides Market Revenue (USD billion) Forecast, by Generation, 2021-2034
  • Table 12: Europe Aminoglycosides Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 13: Europe Aminoglycosides Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 14: Europe Aminoglycosides Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 15: Europe Aminoglycosides Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Asia Pacific Aminoglycosides Market Revenue (USD billion) Forecast, by Generation, 2021-2034
  • Table 17: Asia Pacific Aminoglycosides Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 18: Asia Pacific Aminoglycosides Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 19: Asia Pacific Aminoglycosides Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Asia Pacific Aminoglycosides Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Latin America Aminoglycosides Market Revenue (USD billion) Forecast, by Generation, 2021-2034
  • Table 22: Latin America Aminoglycosides Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 23: Latin America Aminoglycosides Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 24: Latin America Aminoglycosides Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 25: Latin America Aminoglycosides Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 26: Middle East & Africa Aminoglycosides Market Revenue (USD billion) Forecast, by Generation, 2021-2034
  • Table 27: Middle East & Africa Aminoglycosides Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 28: Middle East & Africa Aminoglycosides Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 29: Middle East & Africa Aminoglycosides Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 30: Middle East & Africa Aminoglycosides Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Aminoglycosides Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Aminoglycosides Market Value Share (%), by Generation, 2025 & 2034
  • Figure 3: Global Aminoglycosides Market Value Share (%), by Application, 2025 & 2034
  • Figure 4: Global Aminoglycosides Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 5: Global Aminoglycosides Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 6: Global Aminoglycosides Market Value Share (%), by Region, 2025 & 2034
  • Figure 7: North America Aminoglycosides Market Value (USD billion), by Generation, 2025 & 2034
  • Figure 8: North America Aminoglycosides Market Value Share (%), by Generation, 2025
  • Figure 9: North America Aminoglycosides Market Value (USD billion), by Application, 2025 & 2034
  • Figure 10: North America Aminoglycosides Market Value Share (%), by Application, 2025
  • Figure 11: North America Aminoglycosides Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 12: North America Aminoglycosides Market Value Share (%), by Route of Administration, 2025
  • Figure 13: North America Aminoglycosides Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 14: North America Aminoglycosides Market Value Share (%), by Distribution Channel, 2025
  • Figure 15: North America Aminoglycosides Market Value (USD billion), By Country, 2025 & 2034
  • Figure 16: North America Aminoglycosides Market Value Share (%), By Country, 2025
  • Figure 17: Europe Aminoglycosides Market Value (USD billion), by Generation, 2025 & 2034
  • Figure 18: Europe Aminoglycosides Market Value Share (%), by Generation, 2025
  • Figure 19: Europe Aminoglycosides Market Value (USD billion), by Application, 2025 & 2034
  • Figure 20: Europe Aminoglycosides Market Value Share (%), by Application, 2025
  • Figure 21: Europe Aminoglycosides Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 22: Europe Aminoglycosides Market Value Share (%), by Route of Administration, 2025
  • Figure 23: Europe Aminoglycosides Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 24: Europe Aminoglycosides Market Value Share (%), by Distribution Channel, 2025
  • Figure 25: Europe Aminoglycosides Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Aminoglycosides Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Aminoglycosides Market Value (USD billion), by Generation, 2025 & 2034
  • Figure 28: Asia Pacific Aminoglycosides Market Value Share (%), by Generation, 2025
  • Figure 29: Asia Pacific Aminoglycosides Market Value (USD billion), by Application, 2025 & 2034
  • Figure 30: Asia Pacific Aminoglycosides Market Value Share (%), by Application, 2025
  • Figure 31: Asia Pacific Aminoglycosides Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 32: Asia Pacific Aminoglycosides Market Value Share (%), by Route of Administration, 2025
  • Figure 33: Asia Pacific Aminoglycosides Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 34: Asia Pacific Aminoglycosides Market Value Share (%), by Distribution Channel, 2025
  • Figure 35: Asia Pacific Aminoglycosides Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Aminoglycosides Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Latin America Aminoglycosides Market Value (USD billion), by Generation, 2025 & 2034
  • Figure 38: Latin America Aminoglycosides Market Value Share (%), by Generation, 2025
  • Figure 39: Latin America Aminoglycosides Market Value (USD billion), by Application, 2025 & 2034
  • Figure 40: Latin America Aminoglycosides Market Value Share (%), by Application, 2025
  • Figure 41: Latin America Aminoglycosides Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 42: Latin America Aminoglycosides Market Value Share (%), by Route of Administration, 2025
  • Figure 43: Latin America Aminoglycosides Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 44: Latin America Aminoglycosides Market Value Share (%), by Distribution Channel, 2025
  • Figure 45: Latin America Aminoglycosides Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America Aminoglycosides Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa Aminoglycosides Market Value (USD billion), by Generation, 2025 & 2034
  • Figure 48: Middle East & Africa Aminoglycosides Market Value Share (%), by Generation, 2025
  • Figure 49: Middle East & Africa Aminoglycosides Market Value (USD billion), by Application, 2025 & 2034
  • Figure 50: Middle East & Africa Aminoglycosides Market Value Share (%), by Application, 2025
  • Figure 51: Middle East & Africa Aminoglycosides Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 52: Middle East & Africa Aminoglycosides Market Value Share (%), by Route of Administration, 2025
  • Figure 53: Middle East & Africa Aminoglycosides Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 54: Middle East & Africa Aminoglycosides Market Value Share (%), by Distribution Channel, 2025
  • Figure 55: Middle East & Africa Aminoglycosides Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 56: Middle East & Africa Aminoglycosides Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 57: Global Aminoglycosides Market Share (%), By Company, 2025